Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
نویسندگان
چکیده
منابع مشابه
Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
UNLABELLED Rheumatoid arthritis is one of the commonest autoimmune diseases. It is a chronic, progressive, systemic inflammatory disorder affecting the synovial joints and typically producing symmetrical arthritis. If left untreated, it leads to joint destruction and thus deformity and disability.In the recent years, advances in molecular biology have led to a variety of new treatment approache...
متن کاملMolecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Monoclonal antibodies against TNFα, including infliximab, adalimumab, golimumab, and certolizumab pegol, are widely used for the treatment of the inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Recently, the crystal structures of TNFα, in complex with the Fab fragments of infliximab and adalimumab, have revealed the molecular mechanisms of these antibody drugs...
متن کاملNeutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis.
OBJECTIVE To evaluate the efficacy and safety of tumor necrosis factor (TNF) inhibition with the p55 TNF receptor fusion protein (TNFr-Ig) for severe sight-threatening noninfectious posterior segment intraocular inflammation. METHODS Seventeen patients with refractory noninfectious posterior segment intraocular inflammation received TNFr-Ig by intravenous infusion in this nonrandomized, open-...
متن کاملObserved Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
OBJECTIVE Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID-axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA. METHODS The RAPID-...
متن کاملAnti-tumor necrosis factor-α agents in noninfectious uveitis.
Anti-tumor necrosis factor-α (anti-TNF-α) agents represent a major breakthrough for the therapeutic management of different autoimmune conditions. Noninfectious uveitis may lead to various sight threatening complications. Hence, from extrapolation of the benefit observed in autoimmune systemic diseases, anti-TNF-α agents are widely used in the treatment of noninfectious uveitis. However, their ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Ophthalmology Case Reports
سال: 2020
ISSN: 2451-9936
DOI: 10.1016/j.ajoc.2020.100633